High-dose chemotherapy beneficial in Hodgkin's disease

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1343, 2002-01, pp. : 17-17

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacodynamics of High-Dose Chemotherapy

Current Drug Metabolism, Vol. 2, Iss. 1, 2001-03 ,pp. : 53-66

Bentham Science Publishers

Access to resources Recommend Favorite

Ibritumomab tiuxetan Y-90 plus high-dose BEAM chemotherapy was well tolerated in older patients with non-Hodgkin's lymphoma

Inpharma, Vol. 1, Iss. 1617, 2007-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of High-Dose Chemotherapy with Autologous Stem Cell Support as Initial Treatment of Aggressive Non-Hodgkin's Lymphoma

By Fagnoni Philippe Milpied Noel

PharmacoEconomics, Vol. 27, Iss. 1, 2009-01 ,pp. : 55-68

Adis International

Access to resources Recommend Favorite

High-dose chemotherapy: no survival benefit

Inpharma, Vol. 1, Iss. 1229, 2000-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

High-Dose Chemotherapy in Breast Cancer

By Lake Diana E. Hudis Clifford A.

Drugs, Vol. 64, Iss. 17, 2004-01 ,pp. : 1851-1860

Adis International

Access to resources Recommend Favorite